Document is current
Any future updates will be listed below
-
Authors
Tassorelli, Cristina
Novick, Diego
Gonderten, Saygin https://orcid.org/0009-0005-5995-5957
Vincent, Maurice
Robinson, Rebecca L.
Martimianaki, Georgia
Pozo Rosich, Patricia
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 21 November 2025
Accepted: 9 April 2026
First Online: 28 April 2026
Declarations
:
: Diego Novick, Saygin Gonderten, Rebecca L. Robinson, and Georgia Martimianaki are employees and minor shareholders of Eli Lilly and Company. Maurice Vincent was an employee and minor shareholder of Eli Lilly and Company when the study was conducted and received travel support from Eli Lilly and Company. Cristina Tassorelli has institutional grants/contracts from AbbVie; has received personal consulting fees from AbbVie, Eli Lilly and Company, Dompé, Ipsen, Lundbeck, Pfizer, Medscape, and Teva; has received payment/honoraria for lectures/presentations/speaker bureaus from AbbVie, Eli Lilly and Company, Teva, Lundbeck, and Pfizer; has received support for attending meetings/travel from AbbVie, Eli Lilly and Company Dompé, Ipsen, Teva, Lundbeck, and Pfizer; and has acted as a personal investigator in trials sponsored by AbbVie, Biohaven, Chordate, Eli Lilly and Company, Ipsen, Lundbeck, Pfizer, and Teva. Patricia Pozo Rosich has received grants/contracts from Instituto Salud Carlos III, PMP FEDER, EraNet Neuron, Teva, Novartis, and AbbVie, all to the Headache Research Group at VHIR; has received consulting fees from AbbVie, Almirall, Dr. Reddy’s, Eli Lilly and Company, Lundbeck, Novartis, Organon, Otsuka Pharmaceuticals, Pfizer, and Teva; and has received payment/honoraria for lectures/presentations/speaker bureaus from Abbvie, Almirall, Dr. Reddy’s, Eli Lilly and Company, Lundbeck, Novartis, Organon, Otsuka Pharmaceuticals, Pfizer, and Teva.
: This study was registered through the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (number EUPAS33068) and was and is still conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Pharmacoepidemiology Practices and applicable laws and regulations of the country or countries [Spain, UK, Germany, and Italy] where the study is being conducted, as appropriate. The study protocol and the consent forms were approved by the shared panel of institutional review boards (IRBs) and country-specific ethics committees (full list is provided in the Supplementary Material). Written informed consent was obtained for all study participants.
